-
1.发明公开IMPROVED TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TREATMENT OF PARKINSON'S DISESE 有权改进的透皮治疗系统治疗帕金森氏病的治疗
公开(公告)号：EP1392256A1
公开(公告)日：2004-03-03
申请号：EP02735338.2
申请日：2002-05-06
IPC分类号： A61K9/70 , A61K31/381
CPC分类号： A61K9/7069 , A61K31/381
摘要： This invention provides the use of a silicone-based transdermal therapeutic system having an area of 10 to 40 cm and containing 0.1 to 3.15 mg / cm of Rotigotine as active ingredient, for the preparation of an anti-Parkinson medicament which effects an improvement, compared to a placebo treatment, of the condition of human Parkinson patients, measured according to the Unified Parkinson's Disease Rating Scale (UPDRS) parts II and III, of 2 units or more following administration for a time period of at least 7 weeks.
-
2.发明授权TRANSDERMAL THERAPEUTIC SYSTEM FOR PARKINSON'S DISEASE INDUCING HIGH PLASMA LEVELS OF ROTIGOTINE 无效帕金森病的透皮治疗系统具有高罗替高汀血浆MIRROR
公开(公告)号：EP1471892B1
公开(公告)日：2009-09-30
申请号：EP02740569.5
申请日：2002-05-06
IPC分类号： A61K9/70 , A61K31/381
CPC分类号： A61K9/7061 , A61K9/7069 , A61K31/381
摘要： This invention provides the use of a silicone-based transdermal therapeutic system having an area of 10 to 40 cm2 and containing 0.1 to 3.15 mg/cm2 of rotigotine as active ingredient, for the preparation of an anti-Parkinson medicament which induces a mean plasma concentration of rotigotine in the range of 0.4 to 2 ng/ml 24 h after administration.
-
3.发明授权IMPROVED TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TREATMENT OF PARKINSON'S DISEASE 有权改进的透皮治疗系统治疗帕金森氏病的治疗
公开(公告)号：EP1392256B1
公开(公告)日：2010-04-21
申请号：EP02735338.2
申请日：2002-05-06
IPC分类号： A61K9/70 , A61K31/381
CPC分类号： A61K9/7069 , A61K31/381
摘要： This invention provides the use of a silicone-based transdermal therapeutic system having an area of 10 to 40 cm and containing 0.1 to 3.15 mg / cm of Rotigotine as active ingredient, for the preparation of an anti-Parkinson medicament which effects an improvement, compared to a placebo treatment, of the condition of human Parkinson patients, measured according to the Unified Parkinson's Disease Rating Scale (UPDRS) parts II and III, of 2 units or more following administration for a time period of at least 7 weeks.
-
公开(公告)号：EP1524971B1
公开(公告)日：2006-10-25
申请号：EP03766330.9
申请日：2003-07-28
申请人： SCHWARZ PHARMA AG
CPC分类号： A61K9/7061 , A61K9/7069 , A61K31/38
摘要： An improved Transdermal Delivery System (TDS) comprising a backing layer inert to the components of the matrix, a self-adhesive matrix containing an amine-functional drug and a protective foil or sheet to be removed priorto use, characterized in that the self-adhesive matrix consists of a solid or semi-solid semi-permeable polymer (1)wherein an amine functional drug in its free base form has been incorporated, (2) which is saturated with the aminefunctional drug and contains said drug as a multitude of microreservoirs within the matrix, (3) which is highly permeable for the free base of the amine functional drug, (4) which is impermeable for the protonated form of the amine functional drug, (5) wherein the maximum diameter of the microreservoirs is less than the thickness of the matrix. is provided. Said TDS provides for enhanced flux of the amine functional drug across the TDS/skin interface.
-
5.发明授权
公开(公告)号：EP1524975B9
公开(公告)日：2012-02-22
申请号：EP03766331.7
申请日：2003-07-28
申请人： SCHWARZ PHARMA AG
CPC分类号： A61K9/7061 , A61K9/7069 , A61K31/38
摘要： An improved Transdermal Delivery System (TDS) comprising a backing layer inert to the components of the matrix, a self-adhesive matrix containing rotigotine and a protective foil or sheet to be removed prior to use, characterized in that the self-adhesive matrix consists of a solid or semi-solid semi-permeable polymer (1) wherein rotigotine in its free base form has been incorporated, (2) which is saturated with rotigotine and contains said rotigotine as a multitude of microreservoirs within the matrix, (3) which is highly permeable for the free base of rotigotine, (4) which is impermeable for the protonated form of rotigotine, (5) wherein the maximum diameter of the microreservoirs is less than the thickness of the matrix. is provided. Said TDS provides for enhanced flux of rotigotine across the TDS/skin interface.
-
公开(公告)号：EP1524971A1
公开(公告)日：2005-04-27
申请号：EP03766330.9
申请日：2003-07-28
申请人： SCHWARZ PHARMA AG
CPC分类号： A61K9/7061 , A61K9/7069 , A61K31/38
摘要： An improved Transdermal Delivery System (TDS) comprising a backing layer inert to the components of the matrix, a self-adhesive matrix containing an amine-functional drug and a protective foil or sheet to be removed priorto use, characterized in that the self-adhesive matrix consists of a solid or semi-solid semi-permeable polymer (1)wherein an amine functional drug in its free base form has been incorporated, (2) which is saturated with the aminefunctional drug and contains said drug as a multitude of microreservoirs within the matrix, (3) which is highly permeable for the free base of the amine functional drug, (4) which is impermeable for the protonated form of the amine functional drug, (5) wherein the maximum diameter of the microreservoirs is less than the thickness of the matrix. is provided. Said TDS provides for enhanced flux of the amine functional drug across the TDS/skin interface.
-
7.发明公开
公开(公告)号：EP1524975A1
公开(公告)日：2005-04-27
申请号：EP03766331.7
申请日：2003-07-28
申请人： SCHWARZ PHARMA AG
CPC分类号： A61K9/7061 , A61K9/7069 , A61K31/38
摘要： An improved Transdermal Delivery System (TDS) comprising a backing layer inert to the components of the matrix, a self-adhesive matrix containing rotigotine and a protective foil or sheet to be removed prior to use, characterized in that the self-adhesive matrix consists of a solid or semi-solid semi-permeable polymer (1) wherein rotigotine in its free base form has been incorporated, (2) which is saturated with rotigotine and contains said rotigotine as a multitude of microreservoirs within the matrix, (3) which is highly permeable for the free base of rotigotine, (4) which is impermeable for the protonated form of rotigotine, (5) wherein the maximum diameter of the microreservoirs is less than the thickness of the matrix. is provided. Said TDS provides for enhanced flux of rotigotine across the TDS/skin interface.
-
8.发明公开TRANSDERMAL THERAPEUTIC SYSTEM FOR PARKINSON'S DISEASE INDUCING HIGH PLASMA LEVELS OF ROTIGOTINE 无效帕金森病的透皮治疗系统具有高罗替高汀血浆MIRROR
公开(公告)号：EP1471892A2
公开(公告)日：2004-11-03
申请号：EP02740569.5
申请日：2002-05-06
IPC分类号： A61K9/70 , A61K31/381
CPC分类号： A61K9/7061 , A61K9/7069 , A61K31/381
摘要： This invention provides the use of a silicone-based transdermal therapeutic system having an area of 10 to 40 cm2 and containing 0.1 to 3.15 mg/cm2 of rotigotine as active ingredient, for the preparation of an anti-Parkinson medicament which induces a mean plasma concentration of rotigotine in the range of 0.4 to 2 ng/ml 24 h after administration.
-
公开(公告)号：EP1178782A2
公开(公告)日：2002-02-13
申请号：EP00931217.4
申请日：2000-05-16
申请人： SCHWARZ PHARMA AG
IPC分类号： A61K9/70 , A61K31/135
CPC分类号： A61K9/7061 , A61K9/146 , A61K31/137
摘要： The invention relates to a transdermal therapeutic system (TTS) for transcutaneously administering tolterodine over a period of several days and to a method for producing the same. The TTS contains a self-adhesive layer-shaped matrix material which contains a (meth)acrylate copolymer comprising ammonium groups. The TTS also contains at least one softener and up to 25 wt. % of tolterodine.
-
公开(公告)号：EP1178782B1
公开(公告)日：2006-08-09
申请号：EP00931217.4
申请日：2000-05-16
申请人： SCHWARZ PHARMA AG
IPC分类号： A61K9/70 , A61K31/135
CPC分类号： A61K9/7061 , A61K9/146 , A61K31/137
摘要： The invention relates to a transdermal therapeutic system (TTS) for transcutaneously administering tolterodine over a period of several days and to a method for producing the same. The TTS contains a self-adhesive layer-shaped matrix material which contains a (meth)acrylate copolymer comprising ammonium groups. The TTS also contains at least one softener and up to 25 wt. % of tolterodine.
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.013 秒)
